TDP-43 self-assembles into oligomers that are able to recruit Aβ to form oligomers of its own, claims a paper in the September 12 Nature Communications. Using a new TDP-43 oligomer antibody, the ...
Morning Overview on MSN
Could attacking toxic protein chains finally slow neurodegenerative disease?
Researchers are testing a fundamentally different strategy against neurodegenerative disease: instead of clearing protein deposits after they form, new experimental therapies aim to stop toxic protein ...
In amyotrophic lateral sclerosis and frontotemporal dementia, loss of the RNA-binding protein TDP-43 from the nucleus creates a surge of mis-spliced mRNAs in neurons. So far, only one of these errant ...
The first patient has been dosed in a Phase 1/2 clinical study of VTx-002, an experimental therapy for amyotrophic lateral sclerosis.
Accumulation of a protein called TDP-43 is a key feature of ALS and frontotemporal dementia. In a newly published study, researchers report 'seeding' this accumulation through fragments of the culprit ...
A team of researchers has developed a laboratory model that recapitulates the pathological aggregation of TAR DNA-binding protein 43 (TDP-43), a hallmark of amyotrophic lateral sclerosis (ALS) and ...
Frontotemporal dementia (FTD) is one of the most common causes of progressive dementia in working-age people. However, making a diagnosis and a prognosis is often challenging because the ...
Niigata, Japan - Amyotrophic lateral sclerosis (ALS) is an intractable neurological disease. Aging is a risk factor for the accumulation of TDP-43 (transduction responsive region DNA-binding protein ...
The TDP-43 RNA-binding protein is found in abnormal cytoplasmic inclusions in affected motor neurons in almost all ALS cases, and mutations in the TDP-43 gene (TARDBP) cause a rare form of familial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results